InvestorsHub Logo
Followers 828
Posts 119581
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Monday, 05/09/2016 9:44:26 AM

Monday, May 09, 2016 9:44:26 AM

Post# of 686
CMRX +7% despite weak results in AdVise study of Brincidofovir vs historical control arm in treatment of adenoviris (expectations for this study were very low):

https://finance.yahoo.com/news/chimerix-announces-top-line-interim-113000872.html

Cash and investments at 3/31/16 were $315M. Based on the current share price, the enterprise value is negative.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CMRX News